Transcranial magnetic stimulation is associated with reductions in both anxiety and depression scores in patients with both disorders, a large new analysis shows.
The ALPS Medical Breakthroughs ETF (SBIO) rallied 14.53% last week, propelled by positive earnings and two significant M&A announcements in the portfolio.
This Could Be One of the Best Ways to Treat Mental Health Issues for Millions
Over the last 20 years, “The number of psychopharmacological drugs research programs in larger drug firms has shrunk by 70% in the past decade,” reported The Guardian. “In general the larger companies have walked away from psychiatry. There are a few companies who have maintained efforts in the area but 70% tells you it’s been a pretty remarkable departure. Many withdrew from neuroscience entirely.” Of course, that needs to change, which is why companies like Silo Wellness (CSE:SILO),
Tryp Therapeutics Inc. (CSE:TRYP),
Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), and
Psychedelics Could be Your Next Multi-Billion-Dollar Opportunity
It may only be a matter of time before mind-altering drugs make their way into Big Pharma treatments for mental health issues, such as depression, anxiety, obsessive compulsive disorder, trauma, and addiction. If that happens, the industry could be worth well over $100 billion, as noted by analyst at Eight Capital, benefiting companies such as
Silo Wellness (CSE:SINO),
Compass Pathways Inc. (NASDAQ:CMPS),
HAVN Life Sciences Inc. (CSE:HAVN), and
Tryp Therapeutics Inc. (CSE:TRYP).
Helping even more, a bill to decriminalize psychedelics in California is moving forward. In fact, according to Benzinga, “Introduced in February by Sen. Scott Wiener, SB 519 would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychoactive drugs including psilocybin, psilocyn, DMT, ibogaine, mescaline, LSD, ketamine and MDMA.”
Psilocybin Could be a Major Game Changer for Millions of People
The psychedelics story is quickly gaining momentum. Over the last few months, Denver, Oakland, and Santa Cruz have recently legalized its use. Joining them, Ann Arbor, Michigan lawmakers voted to decriminalize psilocybin mushrooms, as well.
Now, even Florida could soon legalize magic mushrooms by 2022. In fact, according to Miami New Times, “A recent bill introduced by Florida House Rep. Michael Grieco aims to legalize the use of psilocybin, a hallucinogenic substance found in certain types of so-called magic mushrooms, to treat mental illnesses such as depression and anxiety.”
Even the Canadian government allowed four terminally ill patients with cancer to receive psilocybin therapy to help ease end-of-life distress. This is the first time in 46 years that an exemption has been given in Canada for patients to access such treatment. Better, with the FDA’s more open-minded approach to psyched